SEC Filings
Fairmount-Linked Holders Of 9.99% Of Spyre Therapeutics Agree To 60-Day Lock-Up After Offering
Amendment No. 8 to a Schedule 13D reports the lock-up only; the holders did not buy shares and their position is unchanged since June.
SYRE
Spyre Therapeutics (SYRE) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Spyre Therapeutics Prices 4.1 Million Shares At $85.00, Targeting $350.0 Million In Gross Proceeds
An 8-K says the sale funds a late-stage SPY072 program in hidradenitis suppurativa, with closing expected on or about Wednesday.
SEC Filings
Spyre Therapeutics Prices $350 Million Stock Sale At $85 A Share, Below October 2 Price
The 4,117,648 new shares equal about 4.5% of shares outstanding after the offering, and the company lists three disease areas for the money.